Peptide having antihypertensive activity free of vascoconstrictor activity
US5439887A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 10, 1993 |
| Grant date | Aug 8, 1995 |
| Priority date | — |
| Expiry date | Feb 10, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A peptide derivative having the formula: ##STR1## wherein X.sub.1 is hydrogen or cysteine residue, PA1 X.sub.3 is a cysteine or alanine residue, PA1 X.sub.4 is a residue of asparagine, phenylalanine, leucine, isoleucine, alanine, valine, glycine and their homologues in the D series, PA1 X.sub.6 is a residue of tryptophan, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, tyrosine, threonine and their homologues in the D series, PA1 X.sub.9 and X.sub.17 are a residue of glutamic acid, aspartic acid, lysine, arginine, tyrosine, leucine and their homologues in the D series, PA1 X.sub.11 is a cysteine or alanine residue, PA1 X.sub.14 is a residue of tyrosine, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, threonine and their homologues in the D series, PA1 X.sub.21 is hydrogen or a tryptophan or D-tryptophan residue, and the derivatives possessing, where appropriate, one or two disulfide bridges, with the proviso that X.sub.21 cannot be a tryptophan residue when X.sub.1, X.sub.3 and X.sub.11 are a cysteine residue, PA1 X.sub.4 is an asparagine residue, X.sub.6 is a tryptophan residue, X.sub.9 is a …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.